title: [The efficacy of high-dose chemotherapy and the transplantation of autologous hemopoietic cells in lymphogranulomatosis].
abstract: OBJECTIVE
  To determine clinical effectiveness of high-dose polychemotherapy (PCT) and transplantation of autologous hemopoietic cells (TAHC) in patients with lymphogranulomatosis (LGM).
  
  
  METHODS
  27 LGM patients aged 16-42 years who have undergone TAHC after high-dose PCT (BEAM--17 patients or CBV--10 patients). 4 patients given high-dose PCT were in the first-second complete remission (CR), 7 patients--in the first partial remission (PR). Prior to TAHC, 8 patients had one, two and more relapses of LGM, and 8 patients had no remission at all. Bone marrow, hemopoietic blood cells and both were transplanted to 17, 2 and 8 patients, respectively. Mobilization of hemopoietic blood cells and stimulation of hemopoiesis after TAHC were achieved using colony-stimulating factors.
  
  
  RESULTS
  The treatment resulted in CR or PR (from 6 to 95 months) in 70.4% of patients. The remission duration varied depending on the disease phase at transplantation. Four patients who underwent TAHC in PR maintained it for 13-95 months (median 47.5 months). Lasting remissions (29-59 months) were achieved in 42.9 and 37.5% of patients who underwent TAHC in the first PR or in recurrent LGM. None of the patients was in remission longer than 2 years after TAHC if high-dose PCT was conducted in advanced tumor process due to resistant LGM or inadequate previous treatment. Infectious complications lethality early after the transplantation reached 7.4%(2 patients).
  
  
  CONCLUSIONS
  High-dose PCT followed by TAHC is effective in LGM if the tumor is chemosensitive.
authors.forename: L P
authors.initials: LP
authors.lastname: Mendeleeva
authors.forename: V G
authors.initials: VG
authors.lastname: Savchenko
authors.forename: V A
authors.initials: VA
authors.lastname: Rossiev
authors.forename: O A
authors.initials: OA
authors.lastname: Pavlova
authors.forename: I Ia
authors.initials: IIa
authors.lastname: Aleksandrova
authors.forename: K S
authors.initials: KS
authors.lastname: Momotiuk
authors.forename: L S
authors.initials: LS
authors.lastname: Liubimova
authors.forename: G A
authors.initials: GA
authors.lastname: Kliasova
authors.forename: E O
authors.initials: EO
authors.lastname: Gribanova
authors.forename: I A
authors.initials: IA
authors.lastname: Demidova
authors.forename: R G
authors.initials: RG
authors.lastname: Kuliev
authors.forename: I V
authors.initials: IV
authors.lastname: Gal'tseva
authors.forename: L A
authors.initials: LA
authors.lastname: Kuz'mina
authors.forename: I B
authors.initials: IB
authors.lastname: Kaplanskaia
authors.forename: M M
authors.initials: MM
authors.lastname: Petrov
authors.forename: S V
authors.initials: SV
authors.lastname: Varlamova
authors.forename: E M
authors.initials: EM
authors.lastname: Shulutko
authors.forename: S M
authors.initials: SM
authors.lastname: Kulikov
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D005260:Female; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods; D006689:Hodgkin Disease / Q000097:blood / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D012074:Remission Induction; D012189:Retrospective Studies; D013997:Time Factors; D014182:Transplantation, Autologous